Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3847 - Intratumoral heterogeneity of HER2 expression is relevant to breast cancer malignancy

Date

10 Oct 2016

Session

Poster display

Presenters

Mari Hosonaga

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

M. Hosonaga1, Y. Arima2, E. Sato3, K. Yamada1, H. Kaise1, Y. Kawai1, S. Teraoka4, H. Saya2, T. Ishikawa4

Author affiliations

  • 1 Breast Surgical Oncology, Tokyo Medical University Hospital, 160-0023 - Tokyo/JP
  • 2 Division Of Gene Regulation, Institute For Advanced Medical Research, Keio University School of Medicine, Tokyo/JP
  • 3 Pathology, Tokyo Medical University Hospital, Tokyo/JP
  • 4 Breast Surgical Oncology, Tokyo Medical University Hospital, Tokyo/JP
More

Resources

Abstract 3847

Background

Tumor diversity may cause therapeutic resistance and HER2 heterogeneity have been reported to associate with poor prognosis in esophageal adenocarcinomas. We focused on the correlation between HER2 heterogeneity and prognosis in breast cancer.

Methods

To determine the characteristics of heterogeneous overexpression of HER2 in breast cancer, we established two types of HER2-expressing cells, HER2-60 contains 63.2% of HER2-positive cells, and HER2-90 contains 92.4%, by introducing the HER2 gene into a human triple-negative breast cancer cell line, MDA-MB 231. We also investigated correlation between HER2 heterogeneity and tumor malignancy in human breast cancer specimens.

Results

When we inoculate the HER2-60 into the mammary fat pads of nude mice, heterogeneous HER2-expressing tumors developed, while HER2-90 consists mostly of HER2-expressed cells, and developed monotonous HER2-expressing tumors. We found that HER2-60 mice showed shorter survivals than HER2-90 mice, the median survival days after intracardiac injections were 24 (n = 22) and 30 (n = 13), respectively. Next we investigated the correlation between HER2 expression and prognosis in human breast cancer. There were 73 HER2-positive breast cancer patients who received neoadjuvant chemotherapy with trastuzumab and underwent surgery between January 2004 and December 2010 in our hospital. Fifty-five patients showed HER2 3+ by immunohistochemistry and 18 patients showed HER2 2+ and FISH-positive. HER2 2+ patients were divided into 2 groups by the staining pattern, overall and partially stained cases. We defined as HER2 monotonous-type (HER2 mono) and HER2 heterogeneous-type (HER2 hetero), respectively At the median follow-up of 69.1 months, recurrent diseases were found in 25% (14/55) in HER2 3+ cases, and 30% (3/10) in HER2 hetero cases, while no recurrence was found in HER2 mono cases.

Conclusions

Intratumoral HER2 heterogeneity is associated with aggressive breast cancers. Additional therapy should be considered for HER2 hetero breast cancers because HER2-positive breast cancers are all treated with chemotherapy with trastuzumab.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Grants-in-Aid for Scientific Research

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings